Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5463_Библиотеки_им_академика_М_И_Перельмана.pdf
Contributors xi
Kaius Munhoz de Paula
Chinmaya Pradhan
Cleonice Gonçalves da Rosa
Subhasis Roy
Mohanpur, Nadia, India
Érica Gabrieli dos Santos da Silva
Usharani Subuddhi
Tarso Waltrick
Antonio Claudio T edesco
Binita Tirkey
Preface
Advances in Pharmaceutical Technology for Drug Delivery Systems
(PTDDS), Volume 2: Recent Progress in Biomedical Applications covers
3D printing technology, electrospun technology, interpenetrating polymer
-
scientists.
-
neering, biotechnologies, and the pharmaceutical industry.
outstanding capacity to encapsulate both hydrophilic and hydrophobic medi-
-
xiv Preface
cornea) tissue regeneration.
-
protein-based carriers.
-
its derivatives, its cytocompatibility, biocompatibility, and its various appli-
bioimaging, photothermal therapy, and tissue engineering.
-
ingredients used as additives in pharmacology, the most common dosage
tissue engineering.
various biomedical approaches like orthopedic surgery, drug delivery, dental
engineering, biotechnologies, and the pharmaceutical industry.
Advances in Pharmaceutical T echnology for Drug Delivery Systems (PTDDS), Volume 2: Recent Progress
in Biomedical Applications. Sougata Jana (Ed.)
© 2025 Apple Academic Press, Inc. Co-published with CRC Press (Taylor & Francis)
CHAPTER 1
Niosomes in Delivery of Therapeutics
and Biomedical Application
BINITA TIRKEY, CHINMAYA PRADHAN, and USHARANI SUBUDDHI
Department of Chemistry, National Institute of Technology Rourkela,
Rourkela, Odisha, India
ABSTRACT
-
2
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
1.1 INTRODUCTION
1.1.1 WHY NIOSOME?
-
1909 (Uchegbu and Florence, 1995). Since then, numerous drug-delivery
carriers have been developed, including micelles, synthetic polymers,
microspheres, immune globulins, serum proteins, liposomes, and niosomes
(Strebhardt and Ullrich, 2008). Among these, vesicular drug-delivery
systems such as liposomes and niosomes have got remarkable attention
due to their structural uniqueness and bio-relevance (Chen et al., 2012).
have become versatile instruments in biology, biochemistry, and medicine
-
clinical trials, thanks to the ongoing advancements in liposome technology .
-
phospholipids undergo oxidation and hydrolysis leading to degradation
Niosomes in Delivery of Therapeutics and Biomedical Application
3
(Liu et al., 2022). For these reasons, various other amphiphilic compounds
-
., 2012).
FIGURE 1.1
Source
1.1.2 ADVANTAGES OF NIOSOME
b. Niosomes do not trigger immunogenic reactions and can be easily
and biodegradable.
c. Both hydrophilic and hydrophobic medicines can be enclosed in
niosomes.
d. Niosomes can improve the bioavailability by improving the physical
4
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
e. Niosomes can be administered practically through all the routes
including orally, parenterally, transdermally, ocularly, and
pulmonarily.
-
ance is improved.
i. Niosomes can also be designed to administer a medicine in a
targeted, regulated, and sustained manner.
1.1.3 STRUCTURE OF NIOSOME
alkyl ether having a bilayer amphiphilic structure that surround an aqueous
-
both hydrophilic and hydrophobic medications. Hydrophilic medicines can
1. Small unilamellar vesicles (20–50 nm in diameter)
2. Large unilamellar vesicles (50–1000 nm in diameter)
3. MLVs (multilamellar vesicles) (1–20 µm in diameter)
Niosomes can be produced using various preparation methods such
2022).
Niosomes in Delivery of Therapeutics and Biomedical Application
5
FIGURE 1.2
sites.
Source
1.1.4 COMPONENTS OF NIOSOME
to use the essential components required to construct a niosome and their
cholesterol, and charge-inducing molecules are mostly the basic components
-
-
inhibiting p
and morusin (Sharma et al.
6
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
•
• Spans (20, 40, 60, 80, 85)
•
-
-
cholesterol to be added is determined by the hydrophilic-lipophilic balance
niosome production (Seleci et al., 2016).
phosphate (negatively charged), phosphatidic acid (negatively charged),
Niosomes in Delivery of Therapeutics and Biomedical Application
7
1.1.5 FACTORS AFFECTING NIOSOMES
20
h
M
M
×
M
h
and M -
-8 are
., 2012):
0
CPP
c
V
la
=
×